Cargando…
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
INTRODUCTION: Our aim was to investigate the efficacy and safety of upadacitinib (UPA) in patients with either oligo- or polyarticular active psoriatic arthritis (PsA) using routine clinical practice data from an observational, prospective, multicentre study. METHODS: This interim analysis contains...
Autores principales: | Werner, Stephanie G., Baraliakos, Xenofon, Reckert, Sabine, Bohl-Bühler, Martin, Laliberté, Marie-Claude, Girard, Tanya, Jeromin, Katharina, Baschuk, Nikola, Fritz, Björn, Bessette, Louis, Hueber, Axel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654267/ https://www.ncbi.nlm.nih.gov/pubmed/37695506 http://dx.doi.org/10.1007/s40744-023-00589-3 |
Ejemplares similares
-
Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022) -
Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023) -
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022) -
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
por: Baraliakos, Xenofon, et al.
Publicado: (2023) -
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)